Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H20F2N4 |
| Molecular Weight | 354.3964 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC(=CC=C1NC2=NCCC2)C3=CC=C(NC4=NCCC4)C(F)=C3
InChI
InChIKey=NHTMYQFUQFNSKL-UHFFFAOYSA-N
InChI=1S/C20H20F2N4/c21-15-11-13(5-7-17(15)25-19-3-1-9-23-19)14-6-8-18(16(22)12-14)26-20-4-2-10-24-20/h5-8,11-12H,1-4,9-10H2,(H,23,25)(H,24,26)
| Molecular Formula | C20H20F2N4 |
| Molecular Weight | 354.3964 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Liroldine was found effective against both extraintestinal and intestinal amoebiasis in animal models. Its activity against hepatic infection in golden hamsters is comparable with that of different derivatives of nitroimidazoles used for human treatment. Against intestinal amoebiasis in Wistar rats, the activity was superior to nitroimidazoles and chloroquine. Paramomycin was comparable and diloxanide furoate was marginally superior. The comparative in vitro and in vivo studies with standard marketed drugs and liroldine indicate an excellent profile of the compound against experimental amoebiasis.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:26:22 GMT 2025
by
admin
on
Mon Mar 31 18:26:22 GMT 2025
|
| Record UNII |
H7H9M0ICD7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C254
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
H7H9M0ICD7
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY | |||
|
100000082543
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105098
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY | |||
|
C110499
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY | |||
|
DTXSID40146951
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY | |||
|
6013
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY | |||
|
SUB08531MIG
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY | |||
|
65887
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY | |||
|
105102-20-3
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY | |||
|
C66020
Created by
admin on Mon Mar 31 18:26:22 GMT 2025 , Edited by admin on Mon Mar 31 18:26:22 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |